Clinical trials: Newly Diagnosed Breast Cancer
Metastatic Breast Cancer
Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)
This is a Phase 1b/2 study. In Phase 1b portion, subjects will know the treatment they are receiving . Subjects will receive U3-1287 with trastuzumab plus paclitaxel .
- Trial name
- NCT01512199
- Testing
- U3-1287, Trastuzumab, Paclitaxel
- Where
- 8 sites in Argentina, Chile
- Volunteers
- 29 people
- Sponsor
- Daiichi Sankyo
Breast Cancer
Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer
RATIONALE: Ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cancer cell growth. Studying samples of blood and tissue from patients with breast cancer in the laboratory may help doctors learn…
- Trial name
- NCT01009437
- Testing
- ritonavir, therapeutic conventional surgery
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Locally Advanced Malignant Neoplasm, Breast Cancer
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
This study is being conducted in patients with newly diagnosed breast cancer that will be undergoing chemotherapy prior to surgery - neoadjuvant chemotherapy.
- Trial name
- NCT01847001
- Testing
- Propranolol, DOT imaging, Paclitaxel
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Columbia University
Breast Cancer
A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
The investigators propose to conduct a Phase I/randomized Phase II study design in order to test the tolerability and efficacy of AZD0530 (also called saracatinib) when used together with anastrozole in therapy for ER+ and/or…
- Trial name
- NCT01216176
- Testing
- Anastrozole, AZD0530 (saracatinib)
- Where
- 2 sites in United States
- Volunteers
- 71 people
- Sponsor
- Joyce Marie Slingerland, MD
Breast Cancer, Breast Neoplasm
Develop and Evaluate the Effectiveness of a Self-Care Smartphone Application on the Self-Efficacy, and Resilience Among Newly Diagnosed Breast Cancer Patients Undergoing Treatment
This study was to develop and evaluate the self-efficacy and resilience of the Breast Cancer Self-Care App in newly diagnosed breast cancer patients undergoing chemotherapy.
- Conditions
- Breast Cancer, Breast Neoplasm, Breast Malignant Tumor, Resilience
- Trial name
- NCT05576545
- Testing
- The Breast Cancer Self-Care App
- Where
- Taiwan
- Volunteers
- 73 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
A Physical Activity Program Compared to Health Education for Improving Memory and Attention in Hispanic Women With Newly-Diagnosed Stage I-IIIa Breast Cancer, MAMA Trial
This clinical trial compares a physical activity program to a health education program for improving memory and attention in Hispanic women who are 50 years of age or older and are newly-diagnosed with stage I-IIIa breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Cancer-related Cognitive Dysfunction
- Trial name
- NCT07331077
- Testing
- Accelerometry, Aerobic Exercise, Electronic Health Record Review
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic
Breast Cancer
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
HER2 gene amplification increases VEGF production in breast cancers; combined inhibition of HER2 and VEGF enhances response in xenograft models.
- Trial name
- NCT00216047
- Testing
- PTK787, Trastuzumab
- Where
- 8 sites in United States
- Volunteers
- 7 people
- Sponsor
- Hoosier Cancer Research Network
Breast Cancer
Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer
The purpose of this study is to determine pathological response to a maximum of 18 weeks of neoadjuvant therapy using a combination of letrozole and Bevacizumab in post-menopausal women with pathologically confirmed invasive…
- Trial name
- NCT00161291
- Testing
- Letrozole in combination with Bevacizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Alabama at Birmingham
Breast Cancer
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer
The aim of this project is to evaluate tailored primary systemic therapy with sequential nab paclitaxel and epirubicin and cyclophosphamide in early breast cancer. This study will be an open label phase II clinical trial.
- Trial name
- Neonab (NCT01830244)
- Testing
- Nab-Paclitaxel
- Where
- 5 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Barwon Health
Breast Cancer
DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer
The purpose of this study is to learn what effects digoxin (DIG) may have on human breast cancer tissue.
- Trial name
- NCT01763931
- Testing
- Digoxin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer
Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00616967
- Testing
- carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, vorinostat
- Where
- 5 sites in United States
- Volunteers
- 68 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer, Invasive Breast Cancer
Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC
This study is investigational and is not designed to treat cancer. In other words, the study drug, entinostat, is not being given to treat cancer.
- Conditions
- Breast Cancer, Invasive Breast Cancer, ER-Negative PR-Negative HER2-Negative Breast Cancer
- Trial name
- NCT03361800
- Testing
- Entinostat
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Education, Breast Neoplasms
An Online Enhanced Education Tool for Young Women Newly Diagnosed With Breast Cancer
This project proposes to develop and test an internet resource - a supported self-management website - that will guide younger women to relevant knowledge and resources, and provide tools that will help YWBC become more skilled…
- Conditions
- Education, Breast Neoplasms, Internet, Health Resources
- Trial name
- NCT02340494
- Testing
- Online Enhanced Education Tool
- Volunteers
- 200 people
- Sponsor
- Women's College Hospital
The Role of Multimedia on Retention and Comprehension of Key Concepts for Surgical Options in Newly Diagnosed Breast Cancer Patients.
Evaluation of the Use of Multimedia to Enhance Patient and Family Understanding
This study will investigate the potential impact of arts-informed, technology-based patient education material, and specifically, the role of multimedia imagery on patient comprehension, perceived satisfaction, anxiety levels…
- Trial name
- NCT01152775
- Testing
- This group of patients will be exposed to multimedia, No Media
- Where
- 2 sites in Canada
- Volunteers
- 60 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Breast Cancer, Metastatic Breast Cancer
T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases
TUXEDO-4 is an international, multicentric, single arm, phase II study aiming to gather additional solid evidence of Trastuzumab-Deruxtecan (T-DXd) activity in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-low…
- Trial name
- TUXEDO-4 (NCT06048718)
- Testing
- Trastuzumab-Deruxtecan (T-DXd)
- Where
- 13 sites in Austria, Spain
- Volunteers
- 28 people
- Sponsor
- MedSIR
BRCA-Mutated Ovarian Carcinoma, BRIP1 Gene Mutation
Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome
Identification of BRCA mutations in ovarian cancer patients may help guide cancer therapies, prognosis, post-operative screening, and other preventative treatments beyond the initial diagnosis.
- Conditions
- BRCA-Mutated Ovarian Carcinoma, BRIP1 Gene Mutation, MSH2 A636P, MLH1 Gene Mutation
- Trial name
- NCT04009148
- Testing
- CASCADE genetic screening
- Where
- United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Breast Carcinoma
E-Health Support Program (PACK Health Program) in Supporting Patient Reported Symptoms in Newly Diagnosed Patients With Breast Cancer
This trial studies how well an electronic (e)-health support program, called the PACK Health Program, supports patient reported symptoms in newly diagnosed patients with breast cancer.
- Trial name
- NCT05549687
- Testing
- Questionnaire Administration, Supportive Care
- Where
- United States
- Volunteers
- 419 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
MRI in Women With Newly Diagnosed Breast Cancer Prior to Breast Conserving Surgery
To see if performing breast MRI before a lumpectomy will help the surgeon successfully remove the entire cancer with normal tissue margins in a single operation thereby reducing the need for additional surgical procedures.
- Trial name
- NCT00695916
- Testing
- Breast MRI
- Sponsor
- Stanford University
Breast Cancer
A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy
To assess the effects of short term administration of celecoxib 400 mg bid between biopsy and reexcision.
- Trial name
- NCT00328432
- Testing
- celecoxib 400 mg bid
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Kansas
Breast Cancer, Psychosocial Effects of Cancer and Its Treatment
Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions
RATIONALE: Genetics education and counseling may help patients make treatment decisions. It is not yet known how genetic counseling or usual care influence patient treatment decisions for breast cancer.
- Trial name
- NCT00262899
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 4 sites in United States
- Volunteers
- 331 people
- Sponsor
- Georgetown University